Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA-Reference-Cited by-同舟云学术

Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA

Published:2023-03 Issue:4 Volume:15 Page:267-281
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Aggarwal Himani¹^ORCID,Bayo KayOnda²,Han Yimei³^ORCID,Muehlenbein Catherine Elizabeth⁴^ORCID,Zhu Yajun Emily⁵,Kim Jong Seok⁶

Affiliation:

1. Center for Observational & Real-World Evidence, Merck & Co Inc, Rahway, NJ 07065, USA

2. College of Population Health, Thomas Jefferson University, Philadelphia, PA 19104, USA

3. Real World Advanced Analysis, Eli Lilly & Company, Indianapolis, IN 46285, USA

4. Global Medical Affairs, Eli Lilly & Company, Indianapolis, IN 46285, USA

5. Medical Affairs/Real World Evidence Biostatistics, Myovant Sciences, Brisbane, CA 94005, USA

6. Clinical Development, Oncology, Gilead Sciences, Foster City, CA 94404, USA

Abstract

Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous non-small-cell lung cancer (NSQ-NSCLC) patients that received pembrolizumab plus pemetrexed-platinum (pembro+pem+plat) aligned with KEYNOTE-189. Materials & methods: OS was evaluated for the overall cohort and maintenance therapy (MT) subgroups and analyzed using Kaplan-Meier estimates and Cox proportional hazards model. Results: Of 2488 patients that received first-line treatment, 45.1% received less than four cycles of pembro+pem+plat, 43.9% received four cycles plus MT with pembro and/or pem, and 11.1% received four cycles without continuing on MT. The median OS was 21.0 months and 9.1 months in patients that continued and did not continue MT. Conclusion: Real world patients that received KEYNOTE-189-aligned treatment had similar OS benefits.

Funder

Eli Lilly and Company

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2022-0166

Reference33 articles.

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for non-small-cell Lung Cancer V.1. MS-79 (2023).

2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

3. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

4. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 single-arm trials;Medicine;2024-07-05

2. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed;European Journal of Cancer;2024-05

3. 89 Pembrolizumab in Metastatic Non-Small Cell Lung Cancer (NSCLC): Real World Data of Patient Outcomes from a District General Hospital;Lung Cancer;2024-04

4. Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer;Immunotherapy;2024-03-15

5. Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice;Frontiers in Oncology;2024-01-23